Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros

Base de dados
Ano de publicação
Tipo de documento
Intervalo de ano de publicação
1.
Int J Mol Sci ; 22(16)2021 Aug 19.
Artigo em Inglês | MEDLINE | ID: mdl-34445640

RESUMO

4-Hexylresorcinol (4HR) has been used as a food additive, however, it has been recently demonstrated as a Class I histone deacetylase inhibitor (HDACi). Unlike other HDACi, 4HR can be taken through foods. Unfortunately, some HDACi have an influence on craniofacial growth, therefore, the purpose of this study was to evaluate the effects of 4HR on craniofacial growth. Saos-2 cells (osteoblast-like cells) were used for the evaluation of HDACi and its associated activities after 4HR administration. For the evaluation of craniofacial growth, 12.8 mg/kg of 4HR was administered weekly to 4 week old rats (male: 10, female: 10) for 12 weeks. Ten rats were used for untreated control (males: 5, females: 5). Body weight was recorded every week. Serum and head samples were collected at 12 weeks after initial administration. Craniofacial growth was evaluated by micro-computerized tomography. Serum was used for ELISA (testosterone and estrogen) and immunoprecipitation high-performance liquid chromatography (IP-HPLC). The administration of 4HR (1-100 µM) showed significant HDACi activity (p < 0.05). Body weight was significantly different in male rats (p < 0.05), and mandibular size was significantly smaller in 4HR-treated male rats with reduced testosterone levels. However, the mandibular size was significantly higher in 4HR treated female rats with increased growth hormone levels. In conclusion, 4HR had HDACi activity in Saos-2 cells. The administration of 4HR on growing rats showed different responses in body weight and mandibular size between sexes.


Assuntos
Anti-Helmínticos/farmacologia , Osso e Ossos/citologia , Ossos Faciais/crescimento & desenvolvimento , Hexilresorcinol/farmacologia , Desenvolvimento Maxilofacial/efeitos dos fármacos , Osteoblastos/citologia , Animais , Osso e Ossos/efeitos dos fármacos , Ossos Faciais/efeitos dos fármacos , Feminino , Masculino , Osteoblastos/efeitos dos fármacos , Ratos
2.
Maxillofac Plast Reconstr Surg ; 43(1): 39, 2021 Nov 01.
Artigo em Inglês | MEDLINE | ID: mdl-34719767

RESUMO

BACKGROUND: 4-hexylresorcinol (4HR) has been shown to have anti-oxidant activity similar to that of resveratrol. As resveratrol increases sirtuin (SIRT) activity, 4HR might behave similarly to resveratrol. METHOD: In this study, the expression levels of SIRT1, SIRT3, and SIRT6 were evaluated after 4HR administration (1-100 µM). As NAD+ is a substrate for SIRTs, its levels with SIRT activity were also studied. RESULTS: In the results, SIRT3 (100 µM at 24 h) and SIRT6 (1-100 µM at 24 h and 10 µM at 8 h) were shown to have significantly higher expression levels compared to untreated control (p < 0.05). Pan-SIRT activity and the NAD+ level was significantly increased compared to that of the untreated control (p < 0.05; 10 and 100 µM at 24 h). CONCLUSION: 4HR administration increased SIRT activity and the NAD+ level in Saos-2 cells.

SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA